Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, 10x Genomics Inc’s stock clocked out at $8.48, up 2.17% from its previous closing price of $8.30. In other words, the price has increased by $2.17 from its previous closing price. On the day, 3.18 million shares were traded. TXG stock price reached its highest trading level at $8.69 during the session, while it also had its lowest trading level at $8.27.
Ratios:
To gain a deeper understanding of TXG’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.26 and its Current Ratio is at 4.97. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.10.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Leerink Partners on February 13, 2025, Downgraded its rating to Market Perform and sets its target price to $12 from $25 previously.
On September 03, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $35.
Jefferies Upgraded its Hold to Buy on July 22, 2024, while the target price for the stock was maintained at $24.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 28 ’25 when Saxonov Serge sold 7,942 shares for $10.63 per share. The transaction valued at 84,393 led to the insider holds 871,540 shares of the business.
Serge Saxonov bought 7,942 shares of TXG for $83,947 on Feb 28 ’25. On Feb 24 ’25, another insider, Hindson Benjamin J., who serves as the insider of the company, sold 4,573 shares for $11.07 each. As a result, the insider received 50,603 and left with 335,324 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TXG now has a Market Capitalization of 1044176256 and an Enterprise Value of 726330624. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.71 while its Price-to-Book (P/B) ratio in mrq is 1.46. Its current Enterprise Value per Revenue stands at 1.189 whereas that against EBITDA is -4.639.
Stock Price History:
The Beta on a monthly basis for TXG is 1.94, which has changed by -0.7103825 over the last 52 weeks, in comparison to a change of 0.097913146 over the same period for the S&P500. Over the past 52 weeks, TXG has reached a high of $29.37, while it has fallen to a 52-week low of $6.78. The 50-Day Moving Average of the stock is -12.23%, while the 200-Day Moving Average is calculated to be -45.55%.
Shares Statistics:
It appears that TXG traded 3.40M shares on average per day over the past three months and 4394620 shares per day over the past ten days. A total of 108.24M shares are outstanding, with a floating share count of 101.85M. Insiders hold about 17.29% of the company’s shares, while institutions hold 86.65% stake in the company. Shares short for TXG as of 1744675200 were 12860779 with a Short Ratio of 3.78, compared to 1741910400 on 12075180. Therefore, it implies a Short% of Shares Outstanding of 12860779 and a Short% of Float of 17.729999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current assessment of 10x Genomics Inc (TXG) involves the perspectives of 2.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is $-0.14, with high estimates of $-0.1 and low estimates of $-0.18.
Analysts are recommending an EPS of between $-0.52 and $-0.55 for the fiscal current year, implying an average EPS of $-0.54. EPS for the following year is $-0.42, with 2.0 analysts recommending between $-0.37 and $-0.47.
Revenue Estimates
In the current quarter, 14 analysts expect revenue to total $132.51M. It ranges from a high estimate of $135.4M to a low estimate of $126.91M. As of the current estimate, 10x Genomics Inc’s year-ago sales were $141.01MFor the next quarter, 14 analysts are estimating revenue of $145.27M. There is a high estimate of $153M for the next quarter, whereas the lowest estimate is $138.47M.
A total of 15 analysts have provided revenue estimates for TXG’s current fiscal year. The highest revenue estimate was $618.98M, while the lowest revenue estimate was $596.84M, resulting in an average revenue estimate of $609.61M. In the same quarter a year ago, actual revenue was $610.78MBased on 15 analysts’ estimates, the company’s revenue will be $664.62M in the next fiscal year. The high estimate is $682M and the low estimate is $640.41M.
